Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 1 - 50 out of 12,693

Document Document Title
WO/2018/013930A1
Embodiments of the present disclosure pertain to methods of opening a lipid bilayer by associating the lipid bilayer with a molecule that includes a moving component capable of moving (e.g., rotating) in response to an external stimulus;...  
WO/2018/011209A1
The invention relates to a further medical use of a polyglycerol derivative, namely to a use for diagnosing a disease at an early stage of the disease by site-specific imaging of angiogenesis, of extracellular matrix remodeling and/or of...  
WO/2018/008311A1
[Problem] To provide 11C-labelled O6-benzylguanine with which PET images can be obtained, and a production method therefor. [Solution] This 11C-labelled O6-benzylguanine is characterized by being represented by chemical formula (a). The ...  
WO/2018/008552A1
[Problem] The purpose of the present invention is to provide: an 11C-labelled catechol derivative exhibiting sufficient radioactivity for obtaining imaging images using a PET device; a PET probe for a phosphorylated tau aggregation inhib...  
WO/2018/009839A1
The invention relates generally to methods of using a thiol -Michael addition hydrogel for providing intracavitary brachytherapy and/or displacing tissue and organs. The thiol-Michael addition hydrogel may be used as a packing material a...  
WO/2018/007258A1
The invention concerns immune complexes for use in a diagnostic method for de- tecting and localizing specific cells or a structure of a tissue in a human or animal body by an imaging technique. First antibodies are directed to an antige...  
WO/2018/005625A1
The present technology is directed to compounds, intermediates thereof, compositions thereof, medicaments thereof, and methods related to the imaging of mammalian tissue overexpressing PSMA. The compounds are of Formula (I) or a pharmace...  
WO/2018/001467A1
A process for producing a fraction containing the pure Mo-99 radioisotope, comprising a basic dissolving of uranium targets with the obtaining of a basic slurry, a filtration of said slurry in order to isolate a basic solution which is a...  
WO/2018/002079A1
There is provided a process for the preparation of a pharmaceutical composition comprising an 18F-labelled gas selected from the group consisting of 18F-labelled sulphur hexafluoride ([18F]SF6) and 18F-labelled carbon tetrafluoride ([18F...  
WO/2018/005732A1
Provided herein are curcumin analogues that are able to interact with amyloid beta (Aβ) and to attenuate the copper-induced crosslinking of Aβ. Also provided herein are methods of using the compounds as imaging agents of amyloid beta a...  
WO/2017/223565A1
The invention provides compositions, kits and methods to treat a hyperproliferative disorder with an agent that increases expression of MCR1 and an MCR1 ligand. The invention also provides a method of treating drug-resistant melanoma, co...  
WO/2017/223357A1
The present technology is directed to compounds, compositions, medicaments, and methods related to the treatment of cancers expressing PSMA. The compounds are of Formulas I & II, or pharmaceutically acceptable salts thereof. The present ...  
WO/2017/220767A1
The present invention relates to the generation of lead-212 for therapeutic use. Specifically, are methods related to the generation of lead-212 based radio labelled proteins, such as radioimmunoconjugates, embodiments of the present inv...  
WO/2017/222398A1
The present invention relates to an isolated cellular targeted delivery system comprising a CD45+ leukocyte cell comprising within said cell a complex of one or more iron binding proteins and an active pharmaceutically active substance a...  
WO/2017/222362A1
The invention relates to a novel radiopharmaceutical that inhibits the prostate-specific membrane antigen (iPSMA), containing hydrazinonicotinamide (HYNIC) as a critical chemical group in increasing in the lipophilicity of the molecule f...  
WO/2017/223092A1
Cerebrospinal fluid (CSF) egress in a patient may be detected in vivo by first intravenously administering a tracer capable of being taken up by brain tissue of the patient and subsequently clearing the brain tissue. The tracer may be de...  
WO/2017/217347A1
The present invention pertains to: an IgG-binding peptide containing a ligand which can be bound to a radioactive metal nuclide; an IgG-binding peptide labeled with a radioactive metal nuclide; a complex of the IgG-binding peptide with I...  
WO/2017/218569A2
The present invention provides peptide conjugates that target an integrin such as αvβ6 integrin. In particular embodiments, the peptide conjugates comprise a moiety such as a PEG moiety, an imaging agent, or a therapeutic agent. The pe...  
WO/2017/214681A1
The present disclosure relates generally to agents that target areas of extracellular matrix turnover in biological tissue and their use for the diagnosis or treatment of conditions associated with extracellular matrix turnover, wherein ...  
WO/2017/214433A1
This invention relates to treatment of cancer using a antibody drug conjugates that comprise PBD molecules in combination with FLT3 inhibitors.  
WO/2017/213247A1
The present invention addresses the problem of providing a technique for detecting a lesion of a heart disease in a non-invasive manner. The present invention provides a non-invasive diagnostic imaging agent for a heart disease, which co...  
WO/2017/210771A1
The present disclosure relates to bisphenol ether derivatives and compositions thereof, which can be useful in radiation therapy for treatment of diseases, such as prostate cancer. In particular, the compounds of the present disclosure c...  
WO/2017/214470A1
Methods, and related compositions, for the improved synthesis of [18F]DCFPyL are disclosed. Also provided are methods, and related compositions, for the use of [18F]DCFPyL so produced.  
WO/2017/211964A1
The present disclosure provides immunogenic compositions, such as vaccines, including DNA vaccines, and uses thereof, e.g., which include an annexin core domain to mediate efficient antigen delivery and antigen presentation in order to i...  
WO/2017/211809A1
The invention provides a method for the formation of a tissue-targeting thorium complex, said method comprising; a) forming an octadentate chelator comprising four hydroxypyridinone (HOPO) moieties, substituted in the N-position with a m...  
WO/2017/210611A1
Described herein are bisphosphonate quinolone conjugates and pharmaceutical formulations thereof that can include a bisphosphonate and a quinolone, where the quinolone can be releasably coupled to the bisphosphonate. Also provided herein...  
WO/2017/210302A1
Provided herein are novel 10Fn3 domains which specifically bind to PD-L1, as well as imaging agents based on the same for diagnostics.  
WO/2017/210335A1
The invention relates to water soluble 18F-prosthetic groups and the synthesis and use 18F-labeled biological molecules containing the 18F-prosthetic groups for imaging various processes within the body, for detecting the location of mol...  
WO/2017/210343A1
In some embodiments herein, methods, compositions, and uses for modulating lymphatic vessels of the central nervous system are described. In some embodiments, methods, compositions, or uses for treating, preventing, or ameliorating sympt...  
WO/2017/205661A1
The invention described herein relates to methods for treating a cancer using one or more compounds comprising a folate receptor binding ligand attached to a drug via a linker. More particularly, the invention described herein relates to...  
WO/2017/203017A1
In the present invention, we solve the problem of facilitating blood pool measurements accessible to patients or researchers by using 18FDG for the in vitro intracellular labeling of RBCs (Red blood cells). 18FDG tracer is available worl...  
WO/2017/205587A1
This invention provides a method for treating a subject afflicted with a hematologic malignancy comprising administering to the subject an agent targeting a hematologic malignancy-associated antigen, wherein the subject has a low periphe...  
WO/2017/200787A1
Provided herein are therapeutic agents having specificity for having inhibitory activity against cancer cells that overexpress human epidermal growth factor receptor (HER) genes, including therapeutic agents comprising one or more HER-ta...  
WO/2017/201375A1
The invention discloses non-iodinated radiopaque microbeads that may be used in image guided embolization in a subject ailing with tumor. The non-iodinated radiopaque microbeads include a ceramic material doped with a CT contrast agent o...  
WO/2017/201441A1
The present invention provides a method of imaging a subject's lung which comprises contacting the subject's lung with a matrix metalloproteinase inhibitor labeled with a radioisotope under conditions such that the inhibitor binds to mat...  
WO/2017/201111A1
The invention relates to the synthesis and use of 18F-labeled millamolecules for imaging various processes within the body, for detecting the location of molecules associated with disease pathology, and for monitoring disease progression...  
WO/2017/195781A1
Provided is a method for reducing the infectiousness of abnormal prion proteins. In this method for reducing the infectiousness of abnormal prion proteins, abnormal prion proteins are brought into contact with functional mineral water th...  
WO/2017/193723A1
Provided are a neutron capture therapy composition (200) and a manufacturing method of the composition (200). The composition (200) comprises at least one nanodiamond (210) and at least one neutron-capture element (220). The at least one...  
WO/2017/197251A1
Highly potent and selective radionuclide-based imaging and therapy agents targeting carbonic anhydrase IX with minimum non-specific organ uptake are disclosed. Methods of imaging and/or treating carbonic anhydrase IX-expressing cells or ...  
WO/2017/196806A1
The present invention is directed to a compound of Formula I or Formula III or a pharmaceutically acceptable ester, amide, solvate, or salt thereof, or a salt of such an ester or amide or a solvate of such an ester amide or salt: wherein...  
WO/2017/196544A1
The present invention includes novel compounds useful for labeling biomolecules. The present invention further includes a novel method of labeling a biomolecule using a compound of the invention. The present invention further includes a ...  
WO/2017/192798A1
The subject matter disclosed herein relates generally to cancer therapy and to anticancer compounds and imaging agents. More specifically, the subject matter disclosed herein relates to agents that target DOR and their use in the treatme...  
WO/2017/192854A1
Radiofluorinated FNDP for PET imaging of soluble epoxide hydrolase (sEH) and method of using the same are disclosed.  
WO/2017/191214A1
The present invention relates to CD31shed for use as a molecular imaging target in the molecular imaging of an inflammatory condition. Administering the radiolabeled peptide P8RI as CD31shed ligand in different rat models of inflammation...  
WO/2017/191572A1
The present invention refers to cells from a subpopulation of progenitors of endothelial cells loaded with gold nanoparticles sensitive to excitation with infrared radiation with consequent release of thermal energy, to a composition com...  
WO/2017/184728A1
An apparatus and method for using rotating shield brachytherapy (RSBT). In an aspect, the RSBT system and method can be used to maintain or increase tumor dose relative to conventional techniques with a dramatic reduction in radiation do...  
WO/2017/183946A1
The present invention relates to an injectable composition for labeling a lesion and a method for providing the information on the position of the lesion using the injectable composition. More specifically, the injectable composition for...  
WO/2017/180492A1
A system, and method, for quantitatively mapping of mitochondrial membrane potential of a tissue in a subject is provided. In some aspects, the provided method includes administering to the subject a detectably effective amount of a trac...  
WO/2017/178343A1
The present invention relates to novel N-[(Pyrimidinylamino)propanyl]- and N-[(Pyridinylamino)propanyl]arylcarboxamide derivatives, processes for their preparation, pharmaceutical compositions containing them and their use in therapy, pa...  
WO/2017/175081A1
The present invention concerns a product enabling a solid implant to be formed, by injection, inside the body of a subject, said product comprising a pharmaceutically acceptable base composition that contains at least a solvent and at le...  

Matches 1 - 50 out of 12,693